世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

細胞分析における画像ベースサイトメトリー市場(エンドユーザー:バイオテクノロジーおよび製薬会社、アカデミア、化粧品業界、研究受託機関、開発・製造受託機関) - 世界の産業分析、規模、シェア、成長、動向、予測、2023年~2031年


Image Based Cytometry in Cell Analysis Market (End-user: Biotechnology & Pharmaceutical Companies, Academia, Cosmetic Industry, Contract Research Organizations, and Contract Development & Manufacturing Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

細胞分析における画像ベースのサイトメトリー市場 - レポートの範囲 TMRの調査レポート「細胞分析における画像ベースのサイトメトリーの世界市場」は、2023年から2031年までの予測期間における市場の指標に関す... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2023年8月23日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
179 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

細胞分析における画像ベースのサイトメトリー市場 - レポートの範囲
TMRの調査レポート「細胞分析における画像ベースのサイトメトリーの世界市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界の細胞分析における画像ベースのサイトメトリー市場の収益を提供しています。また、2023年から2031年までの世界の細胞分析における画像ベースのサイトメトリー市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、細胞分析における画像ベースのサイトメトリー市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照しました。

二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれる。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の細胞分析における画像ベースのサイトメトリー市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、細胞分析における画像ベースのサイトメトリーの世界市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場関係者だけでなく、世界の細胞分析における画像ベースのサイトメトリー市場への参入に関心のある企業にとっても貴重なツールとなります。

当レポートでは、世界の細胞分析における画像ベースのサイトメトリー市場の競争状況について掘り下げています。細胞分析における画像ベースのサイトメトリーの世界市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイル化されています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の細胞分析における画像ベースのサイトメトリー市場におけるプレイヤーの属性です。

細胞分析におけるイメージベースサイトメトリーの世界市場レポートで回答された主な質問
- 予測期間中の全地域における細胞分析における画像ベースのサイトメトリーが生み出す売上/収益は?
- 細胞分析における画像ベースのサイトメトリーの世界市場における機会は何か?
- 市場の主な促進要因、阻害要因、機会、脅威は何か?
- 予測期間中に最も速いCAGRで拡大する地域市場はどこか?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは?
- 世界市場で事業を展開する各企業の市場ポジションは?

細胞分析における画像ベースサイトメトリー市場 - 調査目的と調査アプローチ
細胞分析における画像ベースのサイトメトリーの世界市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーや販売業者、製品承認に関する規制シナリオについて詳細に解説しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。

当レポートでは、細胞分析における画像ベースのサイトメトリーの世界市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点での各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の細胞分析における画像ベースのサイトメトリー市場への投資について、情報に基づいたビジネス上の意思決定を行うことが可能になります。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
    3.1. Overview
    3.2. Market Dynamics
        3.2.1. Drivers
        3.2.2. Restraints
        3.2.3. Opportunities
4. Global Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by End-user
    4.1. Introduction & Definition
    4.2. Key Findings/Developments
    4.3. Market Value Forecast, by End-user, 2017-2031
        4.3.1. Biotechnology & Pharmaceutical Companies
        4.3.2. Academia
        4.3.3. Cosmetic Industry
        4.3.4. Contract Research Organizations
        4.3.5. Contract Development & Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Therapeutic Area
    5.1. Introduction & Definition
    5.2. Key Findings/Developments
    5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
        5.3.1. Oncology & Immune-oncology
            5.3.1.1. Small Molecules
            5.3.1.2. Protein-based Therapeutics
            5.3.1.3. Cell Therapy
            5.3.1.4. Nucleic Acid-based Drugs
        5.3.2. Cardiovascular & Metabolic Diseases
            5.3.2.1. Small Molecules
            5.3.2.2. Protein-based Therapeutics
            5.3.2.3. Cell Therapy
            5.3.2.4. Nucleic Acid-based Drugs
        5.3.3. Immunology
            5.3.3.1. Small Molecules
            5.3.3.2. Protein-based Therapeutics
            5.3.3.3. Cell Therapy
            5.3.3.4. Nucleic Acid-based Drugs
        5.3.4. Rare Diseases
            5.3.4.1. Small Molecules
            5.3.4.2. Protein-based Therapeutics
            5.3.4.3. Cell Therapy
            5.3.4.4. Nucleic Acid-based Drugs
        5.3.5. Neurological Diseases
            5.3.5.1. Small Molecules
            5.3.5.2. Protein-based Therapeutics
            5.3.5.3. Cell Therapy
            5.3.5.4. Nucleic Acid-based Drugs
        5.3.6. Others
            5.3.6.1. Small Molecules
            5.3.6.2. Protein-based Therapeutics
            5.3.6.3. Cell Therapy
            5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Workplace
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Workplace, 2016-2031
        6.3.1. Target Identification
        6.3.2. Hit Generation & Lead Identification
        6.3.3. Lead Optimization
        6.3.4. In Vitro Preclinical Studies
        6.3.5. In Vivo Preclinical Studies
        6.3.6. Clinical Studies
7. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Country/Region
    7.1. Key Findings
    7.2. Market Value Forecast, by Country/Region, 2017-2031
        7.2.1. U.S.
        7.2.2. Europe
        7.2.3. China
        7.2.4. Rest of the World
8. U.S. Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    8.1. Introduction
        8.1.1. Key Findings
    8.2. Market Value Forecast, by End-user, 2017-2031
        8.2.1. Biotechnology & Pharmaceutical Companies
        8.2.2. Academia
        8.2.3. Cosmetic Industry
        8.2.4. Contract Research Organizations
        8.2.5. Contract Development & Manufacturing Organizations
    8.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        8.3.1. Oncology & Immune-oncology
            8.3.1.1. Small Molecules
            8.3.1.2. Protein-based Therapeutics
            8.3.1.3. Cell Therapy
            8.3.1.4. Nucleic Acid-based Drugs
        8.3.2. Cardiovascular & Metabolic Diseases
            8.3.2.1. Small Molecules
            8.3.2.2. Protein-based Therapeutics
            8.3.2.3. Cell Therapy
            8.3.2.4. Nucleic Acid-based Drugs
        8.3.3. Immunology
            8.3.3.1. Small Molecules
            8.3.3.2. Protein-based Therapeutics
            8.3.3.3. Cell Therapy
            8.3.3.4. Nucleic Acid-based Drugs
        8.3.4. Rare Diseases
            8.3.4.1. Small Molecules
            8.3.4.2. Protein-based Therapeutics
            8.3.4.3. Cell Therapy
            8.3.4.4. Nucleic Acid-based Drugs
        8.3.5. Neurological Diseases
            8.3.5.1. Small Molecules
            8.3.5.2. Protein-based Therapeutics
            8.3.5.3. Cell Therapy
            8.3.5.4. Nucleic Acid-based Drugs
        8.3.6. Others
            8.3.6.1. Small Molecules
            8.3.6.2. Protein-based Therapeutics
            8.3.6.3. Cell Therapy
            8.3.6.4. Nucleic Acid-based Drugs
    8.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        8.4.1. Target Identification
        8.4.2. Hit Generation & Lead Identification
        8.4.3. Lead Optimization
        8.4.4. In Vitro Preclinical Studies
        8.4.5. In Vivo Preclinical Studies
        8.4.6. Clinical Studies
9. Europe Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by End-user, 2017-2031
        9.2.1. Biotechnology & Pharmaceutical Companies
        9.2.2. Academia
        9.2.3. Cosmetic Industry
        9.2.4. Contract Research Organizations
        9.2.5. Contract Development & Manufacturing Organizations
    9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        9.3.1. Oncology & Immune-oncology
            9.3.1.1. Small Molecules
            9.3.1.2. Protein-based Therapeutics
            9.3.1.3. Cell Therapy
            9.3.1.4. Nucleic Acid-based Drugs
        9.3.2. Cardiovascular & Metabolic Diseases
            9.3.2.1. Small Molecules
            9.3.2.2. Protein-based Therapeutics
            9.3.2.3. Cell Therapy
            9.3.2.4. Nucleic Acid-based Drugs
        9.3.3. Immunology
            9.3.3.1. Small Molecules
            9.3.3.2. Protein-based Therapeutics
            9.3.3.3. Cell Therapy
            9.3.3.4. Nucleic Acid-based Drugs
        9.3.4. Rare Diseases
            9.3.4.1. Small Molecules
            9.3.4.2. Protein-based Therapeutics
            9.3.4.3. Cell Therapy
            9.3.4.4. Nucleic Acid-based Drugs
        9.3.5. Neurological Diseases
            9.3.5.1. Small Molecules
            9.3.5.2. Protein-based Therapeutics
            9.3.5.3. Cell Therapy
            9.3.5.4. Nucleic Acid-based Drugs
        9.3.6. Others
            9.3.6.1. Small Molecules
            9.3.6.2. Protein-based Therapeutics
            9.3.6.3. Cell Therapy
            9.3.6.4. Nucleic Acid-based Drugs
    9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        9.4.1. Target Identification
        9.4.2. Hit Generation & Lead Identification
        9.4.3. Lead Optimization
        9.4.4. In Vitro Preclinical Studies
        9.4.5. In Vivo Preclinical Studies
        9.4.6. Clinical Studies
    9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
        9.5.1. EU5
        9.5.2. U.K.
        9.5.3. Switzerland
        9.5.4. Rest of Europe
10. China Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by End-user, 2017-2031
        10.2.1. Biotechnology & Pharmaceutical Companies
        10.2.2. Academia
        10.2.3. Cosmetic Industry
        10.2.4. Contract Research Organizations
        10.2.5. Contract Development & Manufacturing Organizations
    10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        10.3.1. Oncology & Immune-oncology
            10.3.1.1. Small Molecules
            10.3.1.2. Protein-based Therapeutics
            10.3.1.3. Cell Therapy
            10.3.1.4. Nucleic Acid-based Drugs
        10.3.2. Cardiovascular & Metabolic Diseases
            10.3.2.1. Small Molecules
            10.3.2.2. Protein-based Therapeutics
            10.3.2.3. Cell Therapy
            10.3.2.4. Nucleic Acid-based Drugs
        10.3.3. Immunology
            10.3.3.1. Small Molecules
            10.3.3.2. Protein-based Therapeutics
            10.3.3.3. Cell Therapy
            10.3.3.4. Nucleic Acid-based Drugs
            10.3.3.5. Nucleic Acid
        10.3.4. Rare Diseases
            10.3.4.1. Small Molecules
            10.3.4.2. Protein-based Therapeutics
            10.3.4.3. Cell Therapy
            10.3.4.4. Nucleic Acid-based Drugs
        10.3.5. Neurological Diseases
            10.3.5.1. Small Molecules
            10.3.5.2. Protein-based Therapeutics
            10.3.5.3. Cell Therapy
            10.3.5.4. Nucleic Acid-based Drugs
        10.3.6. Others
            10.3.6.1. Small Molecules
            10.3.6.2. Protein-based Therapeutics
            10.3.6.3. Cell Therapy
            10.3.6.4. Nucleic Acid-based Drugs
    10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        10.4.1. Target Identification
        10.4.2. Hit Generation & Lead Identification
        10.4.3. Lead Optimization
        10.4.4. In Vitro Preclinical Studies
        10.4.5. In Vivo Preclinical Studies
        10.4.6. Clinical Studies
11. Rest of the World Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by End-user, 2017-2031
        11.2.1. Biotechnology & Pharmaceutical Companies
        11.2.2. Academia
        11.2.3. Cosmetic Industry
        11.2.4. Contract Research Organizations
        11.2.5. Contract Development & Manufacturing Organizations
    11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        11.3.1. Oncology & Immune-oncology
            11.3.1.1. Small Molecules
            11.3.1.2. Protein-based Therapeutics
            11.3.1.3. Cell Therapy
            11.3.1.4. Nucleic Acid-based Drugs
        11.3.2. Cardiovascular & Metabolic Diseases
            11.3.2.1. Small Molecules
            11.3.2.2. Protein-based Therapeutics
            11.3.2.3. Cell Therapy
            11.3.2.4. Nucleic Acid-based Drugs
        11.3.3. Immunology
            11.3.3.1. Small Molecules
            11.3.3.2. Protein-based Therapeutics
            11.3.3.3. Cell Therapy
            11.3.3.4. Nucleic Acid-based Drugs
        11.3.4. Rare Diseases
            11.3.4.1. Small Molecules
            11.3.4.2. Protein-based Therapeutics
            11.3.4.3. Cell Therapy
            11.3.4.4. Nucleic Acid-based Drugs
        11.3.5. Neurological Diseases
            11.3.5.1. Small Molecules
            11.3.5.2. Protein-based Therapeutics
            11.3.5.3. Cell Therapy
            11.3.5.4. Nucleic Acid-based Drugs
        11.3.6. Others
            11.3.6.1. Small Molecules
            11.3.6.2. Protein-based Therapeutics
            11.3.6.3. Cell Therapy
            11.3.6.4. Nucleic Acid-based Drugs
    11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        11.4.1. Target Identification
        11.4.2. Hit Generation & Lead Identification
        11.4.3. Lead Optimization
        11.4.4. In Vitro Preclinical Studies
        11.4.5. In Vivo Preclinical Studies
        11.4.6. Clinical Studies
12. Competition Landscape
    12.1. Market Share Analysis, by Company (2022)
    12.2. Company Profiles
        12.2.1. Nanolive SA
            12.2.1.1. Company Overview
            12.2.1.2. Product Portfolio/Brands with its Description/Features
            12.2.1.3. Strategic Overview/Recent Developments
            12.2.1.4. SWOT Analysis
        12.2.2. PerkinElmer, Inc.
            12.2.2.1. Company Overview
            12.2.2.2. Product Portfolio/Brands with its Description/Features
            12.2.2.3. Financial Overview
            12.2.2.4. Strategic Overview/Recent Developments
            12.2.2.5. SWOT Analysis
        12.2.3. Sartorius AG
            12.2.3.1. Company Overview
            12.2.3.2. Product Portfolio/Brands with its Description/Features
            12.2.3.3. Financial Overview
            12.2.3.4. Strategic Overview/Recent Developments
            12.2.3.5. SWOT Analysis
        12.2.4. Thermo Fisher Scientific Inc.
            12.2.4.1. Company Overview
            12.2.4.2. Product Portfolio/Brands with its Description/Features
            12.2.4.3. Financial Overview
            12.2.4.4. Strategic Overview/Recent Developments
            12.2.4.5. SWOT Analysis
        12.2.5. Merck KGaA
            12.2.5.1. Company Overview
            12.2.5.2. Product Portfolio/Brands with its Description/Features
            12.2.5.3. Financial Overview
            12.2.5.4. Strategic Overview/Recent Developments
            12.2.5.5. SWOT Analysis
        12.2.6. Charles River Laboratories
            12.2.6.1. Company Overview
            12.2.6.2. Product Portfolio/Brands with its Description/Features
            12.2.6.3. Financial Overview
            12.2.6.4. SWOT Analysis
        12.2.7. Yokogawa Electric Corporation
            12.2.7.1. Company Overview
            12.2.7.2. Product Portfolio/Brands with its Description/Features
            12.2.7.3. Financial Overview
            12.2.7.4. SWOT Analysis
        12.2.8. Carl Zeiss AG
            12.2.8.1. Company Overview
            12.2.8.2. Product Portfolio/Brands with its Description/Features
            12.2.8.3. Financial Overview
            12.2.8.4. Strategic Overview/Recent Developments
            12.2.8.5. SWOT Analysis

 

ページTOPに戻る


 

Summary

Image Based Cytometry in Cell Analysis Market – Scope of Report
TMR’s report on the global image based cytometry in cell analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global image based cytometry in cell analysis market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global image based cytometry in cell analysis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the image based cytometry in cell analysis market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global image based cytometry in cell analysis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global image based cytometry in cell analysis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global image based cytometry in cell analysis market.

The report delves into the competitive landscape of the global image based cytometry in cell analysis market. Key players operating in the global image based cytometry in cell analysis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global image based cytometry in cell analysis market profiled in this report.

Key Questions Answered in Global Image Based Cytometry in Cell Analysis Market Report
• What is the sales/revenue generated by image based cytometry in cell analysis across all regions during the forecast period?
• What are the opportunities in the global image based cytometry in cell analysis market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Image Based Cytometry in Cell Analysis Market – Research Objectives and Research Approach
The comprehensive report on the global image based cytometry in cell analysis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global image based cytometry in cell analysis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global image based cytometry in cell analysis market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
    3.1. Overview
    3.2. Market Dynamics
        3.2.1. Drivers
        3.2.2. Restraints
        3.2.3. Opportunities
4. Global Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by End-user
    4.1. Introduction & Definition
    4.2. Key Findings/Developments
    4.3. Market Value Forecast, by End-user, 2017-2031
        4.3.1. Biotechnology & Pharmaceutical Companies
        4.3.2. Academia
        4.3.3. Cosmetic Industry
        4.3.4. Contract Research Organizations
        4.3.5. Contract Development & Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Therapeutic Area
    5.1. Introduction & Definition
    5.2. Key Findings/Developments
    5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
        5.3.1. Oncology & Immune-oncology
            5.3.1.1. Small Molecules
            5.3.1.2. Protein-based Therapeutics
            5.3.1.3. Cell Therapy
            5.3.1.4. Nucleic Acid-based Drugs
        5.3.2. Cardiovascular & Metabolic Diseases
            5.3.2.1. Small Molecules
            5.3.2.2. Protein-based Therapeutics
            5.3.2.3. Cell Therapy
            5.3.2.4. Nucleic Acid-based Drugs
        5.3.3. Immunology
            5.3.3.1. Small Molecules
            5.3.3.2. Protein-based Therapeutics
            5.3.3.3. Cell Therapy
            5.3.3.4. Nucleic Acid-based Drugs
        5.3.4. Rare Diseases
            5.3.4.1. Small Molecules
            5.3.4.2. Protein-based Therapeutics
            5.3.4.3. Cell Therapy
            5.3.4.4. Nucleic Acid-based Drugs
        5.3.5. Neurological Diseases
            5.3.5.1. Small Molecules
            5.3.5.2. Protein-based Therapeutics
            5.3.5.3. Cell Therapy
            5.3.5.4. Nucleic Acid-based Drugs
        5.3.6. Others
            5.3.6.1. Small Molecules
            5.3.6.2. Protein-based Therapeutics
            5.3.6.3. Cell Therapy
            5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Workplace
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Workplace, 2016-2031
        6.3.1. Target Identification
        6.3.2. Hit Generation & Lead Identification
        6.3.3. Lead Optimization
        6.3.4. In Vitro Preclinical Studies
        6.3.5. In Vivo Preclinical Studies
        6.3.6. Clinical Studies
7. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Country/Region
    7.1. Key Findings
    7.2. Market Value Forecast, by Country/Region, 2017-2031
        7.2.1. U.S.
        7.2.2. Europe
        7.2.3. China
        7.2.4. Rest of the World
8. U.S. Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    8.1. Introduction
        8.1.1. Key Findings
    8.2. Market Value Forecast, by End-user, 2017-2031
        8.2.1. Biotechnology & Pharmaceutical Companies
        8.2.2. Academia
        8.2.3. Cosmetic Industry
        8.2.4. Contract Research Organizations
        8.2.5. Contract Development & Manufacturing Organizations
    8.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        8.3.1. Oncology & Immune-oncology
            8.3.1.1. Small Molecules
            8.3.1.2. Protein-based Therapeutics
            8.3.1.3. Cell Therapy
            8.3.1.4. Nucleic Acid-based Drugs
        8.3.2. Cardiovascular & Metabolic Diseases
            8.3.2.1. Small Molecules
            8.3.2.2. Protein-based Therapeutics
            8.3.2.3. Cell Therapy
            8.3.2.4. Nucleic Acid-based Drugs
        8.3.3. Immunology
            8.3.3.1. Small Molecules
            8.3.3.2. Protein-based Therapeutics
            8.3.3.3. Cell Therapy
            8.3.3.4. Nucleic Acid-based Drugs
        8.3.4. Rare Diseases
            8.3.4.1. Small Molecules
            8.3.4.2. Protein-based Therapeutics
            8.3.4.3. Cell Therapy
            8.3.4.4. Nucleic Acid-based Drugs
        8.3.5. Neurological Diseases
            8.3.5.1. Small Molecules
            8.3.5.2. Protein-based Therapeutics
            8.3.5.3. Cell Therapy
            8.3.5.4. Nucleic Acid-based Drugs
        8.3.6. Others
            8.3.6.1. Small Molecules
            8.3.6.2. Protein-based Therapeutics
            8.3.6.3. Cell Therapy
            8.3.6.4. Nucleic Acid-based Drugs
    8.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        8.4.1. Target Identification
        8.4.2. Hit Generation & Lead Identification
        8.4.3. Lead Optimization
        8.4.4. In Vitro Preclinical Studies
        8.4.5. In Vivo Preclinical Studies
        8.4.6. Clinical Studies
9. Europe Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by End-user, 2017-2031
        9.2.1. Biotechnology & Pharmaceutical Companies
        9.2.2. Academia
        9.2.3. Cosmetic Industry
        9.2.4. Contract Research Organizations
        9.2.5. Contract Development & Manufacturing Organizations
    9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        9.3.1. Oncology & Immune-oncology
            9.3.1.1. Small Molecules
            9.3.1.2. Protein-based Therapeutics
            9.3.1.3. Cell Therapy
            9.3.1.4. Nucleic Acid-based Drugs
        9.3.2. Cardiovascular & Metabolic Diseases
            9.3.2.1. Small Molecules
            9.3.2.2. Protein-based Therapeutics
            9.3.2.3. Cell Therapy
            9.3.2.4. Nucleic Acid-based Drugs
        9.3.3. Immunology
            9.3.3.1. Small Molecules
            9.3.3.2. Protein-based Therapeutics
            9.3.3.3. Cell Therapy
            9.3.3.4. Nucleic Acid-based Drugs
        9.3.4. Rare Diseases
            9.3.4.1. Small Molecules
            9.3.4.2. Protein-based Therapeutics
            9.3.4.3. Cell Therapy
            9.3.4.4. Nucleic Acid-based Drugs
        9.3.5. Neurological Diseases
            9.3.5.1. Small Molecules
            9.3.5.2. Protein-based Therapeutics
            9.3.5.3. Cell Therapy
            9.3.5.4. Nucleic Acid-based Drugs
        9.3.6. Others
            9.3.6.1. Small Molecules
            9.3.6.2. Protein-based Therapeutics
            9.3.6.3. Cell Therapy
            9.3.6.4. Nucleic Acid-based Drugs
    9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        9.4.1. Target Identification
        9.4.2. Hit Generation & Lead Identification
        9.4.3. Lead Optimization
        9.4.4. In Vitro Preclinical Studies
        9.4.5. In Vivo Preclinical Studies
        9.4.6. Clinical Studies
    9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
        9.5.1. EU5
        9.5.2. U.K.
        9.5.3. Switzerland
        9.5.4. Rest of Europe
10. China Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by End-user, 2017-2031
        10.2.1. Biotechnology & Pharmaceutical Companies
        10.2.2. Academia
        10.2.3. Cosmetic Industry
        10.2.4. Contract Research Organizations
        10.2.5. Contract Development & Manufacturing Organizations
    10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        10.3.1. Oncology & Immune-oncology
            10.3.1.1. Small Molecules
            10.3.1.2. Protein-based Therapeutics
            10.3.1.3. Cell Therapy
            10.3.1.4. Nucleic Acid-based Drugs
        10.3.2. Cardiovascular & Metabolic Diseases
            10.3.2.1. Small Molecules
            10.3.2.2. Protein-based Therapeutics
            10.3.2.3. Cell Therapy
            10.3.2.4. Nucleic Acid-based Drugs
        10.3.3. Immunology
            10.3.3.1. Small Molecules
            10.3.3.2. Protein-based Therapeutics
            10.3.3.3. Cell Therapy
            10.3.3.4. Nucleic Acid-based Drugs
            10.3.3.5. Nucleic Acid
        10.3.4. Rare Diseases
            10.3.4.1. Small Molecules
            10.3.4.2. Protein-based Therapeutics
            10.3.4.3. Cell Therapy
            10.3.4.4. Nucleic Acid-based Drugs
        10.3.5. Neurological Diseases
            10.3.5.1. Small Molecules
            10.3.5.2. Protein-based Therapeutics
            10.3.5.3. Cell Therapy
            10.3.5.4. Nucleic Acid-based Drugs
        10.3.6. Others
            10.3.6.1. Small Molecules
            10.3.6.2. Protein-based Therapeutics
            10.3.6.3. Cell Therapy
            10.3.6.4. Nucleic Acid-based Drugs
    10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        10.4.1. Target Identification
        10.4.2. Hit Generation & Lead Identification
        10.4.3. Lead Optimization
        10.4.4. In Vitro Preclinical Studies
        10.4.5. In Vivo Preclinical Studies
        10.4.6. Clinical Studies
11. Rest of the World Image-based Cytometry in Cell Analysis Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by End-user, 2017-2031
        11.2.1. Biotechnology & Pharmaceutical Companies
        11.2.2. Academia
        11.2.3. Cosmetic Industry
        11.2.4. Contract Research Organizations
        11.2.5. Contract Development & Manufacturing Organizations
    11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        11.3.1. Oncology & Immune-oncology
            11.3.1.1. Small Molecules
            11.3.1.2. Protein-based Therapeutics
            11.3.1.3. Cell Therapy
            11.3.1.4. Nucleic Acid-based Drugs
        11.3.2. Cardiovascular & Metabolic Diseases
            11.3.2.1. Small Molecules
            11.3.2.2. Protein-based Therapeutics
            11.3.2.3. Cell Therapy
            11.3.2.4. Nucleic Acid-based Drugs
        11.3.3. Immunology
            11.3.3.1. Small Molecules
            11.3.3.2. Protein-based Therapeutics
            11.3.3.3. Cell Therapy
            11.3.3.4. Nucleic Acid-based Drugs
        11.3.4. Rare Diseases
            11.3.4.1. Small Molecules
            11.3.4.2. Protein-based Therapeutics
            11.3.4.3. Cell Therapy
            11.3.4.4. Nucleic Acid-based Drugs
        11.3.5. Neurological Diseases
            11.3.5.1. Small Molecules
            11.3.5.2. Protein-based Therapeutics
            11.3.5.3. Cell Therapy
            11.3.5.4. Nucleic Acid-based Drugs
        11.3.6. Others
            11.3.6.1. Small Molecules
            11.3.6.2. Protein-based Therapeutics
            11.3.6.3. Cell Therapy
            11.3.6.4. Nucleic Acid-based Drugs
    11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        11.4.1. Target Identification
        11.4.2. Hit Generation & Lead Identification
        11.4.3. Lead Optimization
        11.4.4. In Vitro Preclinical Studies
        11.4.5. In Vivo Preclinical Studies
        11.4.6. Clinical Studies
12. Competition Landscape
    12.1. Market Share Analysis, by Company (2022)
    12.2. Company Profiles
        12.2.1. Nanolive SA
            12.2.1.1. Company Overview
            12.2.1.2. Product Portfolio/Brands with its Description/Features
            12.2.1.3. Strategic Overview/Recent Developments
            12.2.1.4. SWOT Analysis
        12.2.2. PerkinElmer, Inc.
            12.2.2.1. Company Overview
            12.2.2.2. Product Portfolio/Brands with its Description/Features
            12.2.2.3. Financial Overview
            12.2.2.4. Strategic Overview/Recent Developments
            12.2.2.5. SWOT Analysis
        12.2.3. Sartorius AG
            12.2.3.1. Company Overview
            12.2.3.2. Product Portfolio/Brands with its Description/Features
            12.2.3.3. Financial Overview
            12.2.3.4. Strategic Overview/Recent Developments
            12.2.3.5. SWOT Analysis
        12.2.4. Thermo Fisher Scientific Inc.
            12.2.4.1. Company Overview
            12.2.4.2. Product Portfolio/Brands with its Description/Features
            12.2.4.3. Financial Overview
            12.2.4.4. Strategic Overview/Recent Developments
            12.2.4.5. SWOT Analysis
        12.2.5. Merck KGaA
            12.2.5.1. Company Overview
            12.2.5.2. Product Portfolio/Brands with its Description/Features
            12.2.5.3. Financial Overview
            12.2.5.4. Strategic Overview/Recent Developments
            12.2.5.5. SWOT Analysis
        12.2.6. Charles River Laboratories
            12.2.6.1. Company Overview
            12.2.6.2. Product Portfolio/Brands with its Description/Features
            12.2.6.3. Financial Overview
            12.2.6.4. SWOT Analysis
        12.2.7. Yokogawa Electric Corporation
            12.2.7.1. Company Overview
            12.2.7.2. Product Portfolio/Brands with its Description/Features
            12.2.7.3. Financial Overview
            12.2.7.4. SWOT Analysis
        12.2.8. Carl Zeiss AG
            12.2.8.1. Company Overview
            12.2.8.2. Product Portfolio/Brands with its Description/Features
            12.2.8.3. Financial Overview
            12.2.8.4. Strategic Overview/Recent Developments
            12.2.8.5. SWOT Analysis

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Transparency Market Research社の医療分野での最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る